Japan Tobacco Inc.

Kenta Aoki

Satoru Noji

Ryo Mizojiri

Kiyotaka Shinoda

Takahiro Oka

Yasushi Niwa

Kazunori Kurihara

Yoko Matsumoto

Toshihiro Sato

Izuru Ando

Masaru Tanaka

Katsuaki Imamura

Hideo Takagi

Yoshitoshi Kodama

Yuichi Naka

Goro Ito

Akihito Fujiwara

The present invention relates to an aminopyridine compound represented by the following general formula (I) or a salt thereof and an Syk inhibitor containing the compound or a salt thereof as an active ingredient. Here, X, X, X, Z, Y, Yrepresent a carbon atom or a nitrogen atom, R, R, R, Rrepresent a hydrogen atom, an alkyl group, etc., and Rrepresents a hydrogen atom, a halogen atom, a nitro group, a cyano group, &#x2014;CH(R)(R)&#x2014;O&#x2014;R, &#x2014;C(&#x2550;O)&#x2014;R, a 5- or 6-membered saturated heterocyclic group, an aromatic heterocyclic group, &#x2014;N(R)(R), etc. The aminopyridine compound of the present invention has not only high Syk inhibitory activity but also properties to selectively inhibit Syk. 

Aminopyridine compounds having Syk inhibitory activity

The present invention relates to a thienopyrrole compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound as an active ingredient. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

Thienopyrrole compound and use thereof as HCV polymerase inhibitor

Growing community of inventors

Takatsuki, Japan

Kenta Aoki